This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
6jhs
From Proteopedia
(Difference between revisions)
| (One intermediate revision not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | The | + | ==The cryo-EM structure of HAV bound to a neutralizing antibody-F7== |
| + | <StructureSection load='6jhs' size='340' side='right'caption='[[6jhs]], [[Resolution|resolution]] 3.05Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[6jhs]] is a 5 chain structure with sequence from [http://en.wikipedia.org/wiki/Human_hepatitis_a_virus_hu/australia/hm175/1976 Human hepatitis a virus hu/australia/hm175/1976] and [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6JHS OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6JHS FirstGlance]. <br> | ||
| + | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6jhs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6jhs OCA], [http://pdbe.org/6jhs PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6jhs RCSB], [http://www.ebi.ac.uk/pdbsum/6jhs PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6jhs ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Hepatitis A virus (HAV), an enigmatic and ancient pathogen, is a major causative agent of acute viral hepatitis worldwide. Although there are effective vaccines, antivirals against HAV infection are still required, especially during fulminant hepatitis outbreaks. A more in-depth understanding of the antigenic characteristics of HAV and the mechanisms of neutralization could aid in the development of rationally designed antiviral drugs targeting HAV. In this paper, 4 new antibodies-F4, F6, F7, and F9-are reported that potently neutralize HAV at 50% neutralizing concentration values (neut50) ranging from 0.1 nM to 0.85 nM. High-resolution cryo-electron microscopy (cryo-EM) structures of HAV bound to F4, F6, F7, and F9, together with results of our previous studies on R10 fragment of antigen binding (Fab)-HAV complex, shed light on the locations and nature of the epitopes recognized by the 5 neutralizing monoclonal antibodies (NAbs). All the epitopes locate within the same patch and are highly conserved. The key structure-activity correlates based on the antigenic sites have been established. Based on the structural data of the single conserved antigenic site and key structure-activity correlates, one promising drug candidate named golvatinib was identified by in silico docking studies. Cell-based antiviral assays confirmed that golvatinib is capable of blocking HAV infection effectively with a 50% inhibitory concentration (IC50) of approximately 1 muM. These results suggest that the single conserved antigenic site from complete HAV capsid is a good antiviral target and that golvatinib could function as a lead compound for anti-HAV drug development. | ||
| - | + | Structural basis for neutralization of hepatitis A virus informs a rational design of highly potent inhibitors.,Cao L, Liu P, Yang P, Gao Q, Li H, Sun Y, Zhu L, Lin J, Su D, Rao Z, Wang X PLoS Biol. 2019 Apr 30;17(4):e3000229. doi: 10.1371/journal.pbio.3000229., eCollection 2019 Apr. PMID:31039149<ref>PMID:31039149</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| - | [[Category: | + | <div class="pdbe-citations 6jhs" style="background-color:#fffaf0;"></div> |
| - | [[Category: | + | == References == |
| - | [[Category: | + | <references/> |
| - | [[Category: | + | __TOC__ |
| - | [[Category: | + | </StructureSection> |
| - | [[Category: | + | [[Category: Human hepatitis a virus hu/australia/hm175/1976]] |
| - | [[Category: | + | [[Category: Large Structures]] |
| - | [[Category: | + | [[Category: Mus musculus]] |
| - | [[Category: | + | [[Category: Cao, L]] |
| - | [[Category: | + | [[Category: Gao, Q]] |
| - | [[Category: | + | [[Category: Li, H]] |
| + | [[Category: Lin, J]] | ||
| + | [[Category: Liu, P]] | ||
| + | [[Category: Rao, Z]] | ||
| + | [[Category: Su, D]] | ||
| + | [[Category: Sun, Y]] | ||
| + | [[Category: Wang, X]] | ||
| + | [[Category: Yang, P]] | ||
| + | [[Category: Zhu, L]] | ||
| + | [[Category: Complex]] | ||
| + | [[Category: Hav]] | ||
| + | [[Category: Icosahedral symmetry]] | ||
| + | [[Category: Neutralizing antibody]] | ||
| + | [[Category: Virus]] | ||
Current revision
The cryo-EM structure of HAV bound to a neutralizing antibody-F7
| |||||||||||
Categories: Human hepatitis a virus hu/australia/hm175/1976 | Large Structures | Mus musculus | Cao, L | Gao, Q | Li, H | Lin, J | Liu, P | Rao, Z | Su, D | Sun, Y | Wang, X | Yang, P | Zhu, L | Complex | Hav | Icosahedral symmetry | Neutralizing antibody | Virus
